Zepbound is not the diabetes-branded tirzepatide product Current FDA labeling indicates Zepbound for long-term weight reduction in adults with obesity or adults with overweight plus at least one weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity
What the evidence says is that in the STEP 1 extension, participants regained roughly two-thirds of their lost weight within a year of stopping, which is why many providers now frame goal weight as the beginning of a maintenance phase rather than the end of treatment
Servings Per Container:31
Then, we summarize clinical data from postmarketting surveillance, randomized controlled trials, and observational studies
This ingredient is available in our Lipo-Mino-Mix-C formulation
The coverage cutoff by Blue Cross Blue Shield of Massachusetts may impact tens of thousands of its members now approved for a class of drugs known as GLP-1s for weight loss, including Ozempic and Wegovy